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ABSTRACT OF THE THESIS
The Stability-Controlled Quasi-Experiment:
Preliminary Report on Applications to
Tuberculosis Prevention in Tanzania
by
David Amichai Wulf
Master of Science in Statistics
University of California, Los Angeles, 2019
Professor Chad J Hazlett, Chair
A new causal inference method called the Stability-Controlled Quasi-Experiment (SCQE)
was recently proposed for identifying the effect of a treatment on units in a population that
are treated. It allows for non-randomized or otherwise unknown means of selection into
treatment, relying only on an assumption about the stability of the non-treatment outcomes
of the population. We apply SCQE to the case of a national public health intervention in
Tanzania to prevent active tuberculosis in HIV-positive patients by prescribing Isoniazid
(IPT). Our preliminary results suggest much of the treatment is given to patients at low risk
for developing active tuberculosis. In the process, we offer best practices and discuss chal-
lenges faced during SCQE implementation. We share steps currently underway to generate
confidence in these results, extend the method further, and derive valid standard errors.
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CHAPTER 1
Introduction
Randomized experiments are the gold standard of research methods when asking about the
effect of a treatment on the outcomes of a group of units. They earn this reputation because
of the causal conclusions they produce without the kind of complex statistical adjustments
and major assumptions required by other causal inference tools. In many cases though,
answering questions with a randomized control trial is either impossible, often because ques-
tions are historical; unethical, particularly in medical applications; or undesirable, usually
because they answer questions about efficacy rather than efficiency. Without randomiza-
tion, researchers running observational studies often face the daunting task of justifying the
selection-on-observables assumption. This is a key claim in many alternate methods which
requires that all differences between the groups of units that did and did not recieve treat-
ment are variables present in the dataset and that they can be controlled for statistically.
Recently, a new method was proposed for making causal claims that avoids this assumption,
replacing it with a different, potentially less stringent assumption, and estimating the effect
on a specific subset of units. In this paper, we apply this new method to estimate the causal
effect of a major public health campaign in Tanzania aimed at preventing tuberculosis. We
utilize the application to demonstrate the types of answers this new method can produce,
as well as to challenge and develop the method.
1.1 The Stability-Controlled Quasi-Experiment
In a 2018 paper [1], Hazlett presented a new identification method to estimate the causal
effect of the introduction (or significant increased use) of a treatment on the outcomes of
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units that were treated. This method does not require randomized cohorts and allows for
any process of treatment assignment or self-selection. The key assumption that replaces
randomization is one of stability: that in lieu of the observed treatment introduction or
increase, we would expect the average outcome to either remain constant or change in a
predictable way counterfactually. The method could be used in two ways: by design, planned
before employing the treatment of interest, or after the fact, applied to observed data.
Hazlett has more recently suggested referring to the method as the Stability-Controlled
Trial (SCT) when used by design, or, as in this paper, as the Stability-Controlled Quasi-
Experiment (SCQE) when it is attempted after the fact. Although the major use case in
both this and the original paper is a medical treatment applied to patients, treatment may
refer to an intervention of any kind. We mirror Hazlett’s use of the potential outcomes
framework[2] and notation here, in which Y is the outcome of interest, D = {0, 1} is a
treatment indicator, Y (D) is the counterfactual outcome under treatment assignment D,
and T = {0, 1} represents the pre- and post-treatment-introduction periods.
As an example of the SCQE, we can imagine a simple case in which a new treatment
was introduced and used by (or assigned to) a proportion pi = Pr(D = 1|T = 1) of the
units in a population in the post-introduction period. Additionally we imagine that, in
this case, had no new treatment been introduced no change in average outcomes would
have been expected. In other words, the average non-treatment outcome in the pre period,
E[Y (0)|T = 0] = E[Y |T = 0], is expected to equal the average non-treatment outcome in the
post period, E[Y (0)|T = 1]. In the pre-period no patients are treated, so the non-treatment
outcomes of the entire population are observed and we can measure the sample average of
these outcomes. In the post-period however some patients are treated, so we do not observe
all patients’ outcomes under non-treatment. For this reason, E[Y (0)|T = 1] is instead a
counterfactual expectation of the entire population’s non-treatment outcomes. The SCQE
explicitly breaks th counterfactual into its observed and unobserved components using the
Law of Iterated Expectations (LIE).
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E[Y (0)|T = 0] = E[Y (0)|T = 1]
= E[Y (0)|T = 1, D = 1]pi + E[Y (0)|T = 1, D = 0](1− pi) (1.1)
Equation 1.1 can be rearranged to identify the wholly counterfactual term, the expected
outcome of the treated patients had they not been treated,
E[Y (0)|T = 1, D = 1] = E[Y (0)|T = 0]− E[Y (0)|T = 1, D = 0](1− pi)
pi
(1.2)
Finally, we can compare this counterfactual average Y (0) for the treated patients and
their observed average Y (1), E[Y (1)|T = 1, D = 1] = E[Y |T = 1, D = 1]. SCQE identifies
the Average Treatment effect on the Treated units (ATT) as the difference between these
terms.
The SCQE does not in fact require the assumption of a counterfactually unchanging
average non-treatment outcome, but only an assumption that this outcome changes over
time in a stable way. In other words, using domain expertise and other data, practitioners
can claim instead that, for a given δ, E[Y (0)|T = 0] + δ = E[Y (0)|T = 1]. This δ can of
course be set to 0 in a case where no change over time in average outcomes would have been
expected in lieu of treatment. Using this notation, the formula for the ATT is identified as:
ATT = E[Y |T = 1, D = 1]−
(
E[Y (0)|T = 0]− E[Y (0)|T = 1, D = 0](1− pi) + δ
pi
)
. (1.3)
Formula 1.3, we can see, only requires five population-level quantities to identify the ATT,
enabling its use by interested parties beyond the original researchers or those with access
to unit-level data. These quantities are often all directly reported or implied in published
articles, and they can be used to obtain an estimate of an effect beyond the one that was
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originally presented. SCQE employs none of the covariate conditioning or weighting that
other methods often use in an attempt to remove differences between treated and untreated
groups. Correspondingly, the validity of its inference relies only on the accuracy of δ, and
not also on the successful use of those adjustment tools. Assuming that δ is 0, for example,
means that there exists strong evidence suggesting no treatment changes were occurring at
this time besides the treatment of interest. This difference in approach also means that great
care must be taken to ensure the pre- and post-period populations can be conceptualized as
draws from the same distribution; any differences between the populations, especially if they
affect the outcome of interest and are unaccounted for by δ, threaten the causal relationship
we hope to ascribe to the change in treatment.
In its simplest form, SCQE can be thought of as an Instrumental Variables (IV) approach,
using time as an instrument. In such a framework, the IV compliers are the treated units,
and we can imagine their presence in the post period as the encouragement to treatment.
The use of time as an instrument is not novel[3, 4, 5, 6, 7], though it is by no means a
common strategy and SCQE adds to this concept in two major ways. First, IV does not
allow for the existence of a non-zero δ, a key feature of the new method. And second,
though it reports the magnitude of the causal effect, IV is not traditionally used to highlight
the treated units’ counterfactual and observed outcomes, which lie on either side of such
an effect. For example, say we learned that a new experimental therapy used to treat a
high-risk cancer increased by 10% the 1-year mortality rate of those who chose to use it.
This information is certainly useful, but it is incomplete without knowing whether that 10%
increase took the treated patients from an 82% to a 92% rate, or from a 17% to a 27%
rate. The SCQE emphasizes these values and the potential they have to direct a study’s key
teachings. This kind of counterfactual thought becomes a priority, and elicits conclusions
that may have been overlooked while using alternative methods.
SCQE can easily be extended from measuring the effect of a new treatment to cases of
rapid increases or decreases in treatment usage. In that case, pi would no longer represent the
treatment usage in the post period. Instead, it would represent the difference in treatment
usage between the post and pre periods. Correspondingly, the ATT would no longer refer to
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the effect of the treatment on units that were treated. In the case of increased application
of treatment it would measure the effect of the treatment on units that were treated in the
post period but would not have been in the pre period. In the case of decreased application
of treatment it would measure the effect of the absence of treatment on units that were not
treated in the post period but would have been in the pre period.
1.2 Tuberculosis prevention in Tanzania
Currently, Tanzania is experiencing a major health crisis in widespread tuberculosis (TB)
and its significant death toll. For those in Tanzania already immunocompromised by HIV,
TB infection is both more likely and more deadly. Several randomized trials have shown
the effectiveness of Isoniazid to treat active TB and to prevent latent TB from developing
into active TB. As a preventative measure, the use of Isoniazid is referred to as Isoniazid
Preventative Therapy (IPT). The World Health Organization strongly encourages the use
of IPT to prevent active TB in those immunocompromised by HIV, even in settings where
testing for latent TB cannot be provided. However, in reality IPT is given to only a small
percentage of those HIV patients who are eligible to receive it[8].
In Tanzania, large-scale efforts to increase IPT use for people living with HIV have
been underway since 2011 in the form of education campaigns. Caregivers at dozens of HIV
treatment facilities across the country were educated about the use of IPT, and instructed to
integrate it into their standard patient care process. These training visits continued to occur
through 2017, incrementally increasing the number of facilities using IPT and the number
of patients given the treatment nationwide. Campaigns like these act on statistically robust
assertions about the efficacy of IPT[9], but little evidence exists to prove that such campaigns
are effective in lowering active TB development (ATBD) rates. Analyses to establish this
have been hampered by a lack of randomization; caregivers only give some HIV patients
IPT, and it is reasonable to presume that some of the determinants of who is given IPT
also determine the likelihood of ATBD. It is exactly this confounding bias that makes such
programs good candidates for SCQE. Dr. Werner Maokola, a Program Officer with the
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National AIDS Control Program in the Ministry of Health Tanzania, agreed to provide the
de-identified data and domain expertise needed to evaluate the campaign using SCQE.
In what follows in Chapter 2, we explain our chosen means of using SCQE to analyze
the IPT program and discuss the various data issues that arose during that pre-analysis
planning. In Chapter 3, we document in detail the various ways we attempted to estimate
δ. In Chapters 4 and 5, we present preliminary results, the conclusions we draw from them,
and application-specific threats to validity. In Chapter 6, we discuss threats to validity and
the work that remains before we can declare these results trustworthy.
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CHAPTER 2
Methods
2.1 SCQE for This Application
We imagined SCQE could be applied here conceptually to estimate two types of causal effects.
It could estimate a single causal effect of new IPT programs on the treated patients at those
facilities that implemented such a program, combining patient data from each facility by
aligning their implementation dates and assuming a constant treatment effect across facilities.
We believed this assumption was likely incorrect, given the sizable differences in size, setting,
staffing, and patient characteristics across HIV facilities in Tanzania, some of which were
bound to affect the implementation or effectiveness of an IPT program. Alternatively, SCQE
could estimate unique causal effects for each implementing facility. We chose to use SCQE
this way, and progressed as follows.
First, we selected each of the facilities (indexed by j) that began use of IPT during our
study period. We use the notation IPTj here to refer to the date that facility j started using
IPT. We then separated the data for each facility into pre-IPTj and post-IPTj cohorts.
The critical requirement was that the cohorts be identical (conceptually, drawn from the
same distribution), so as to ensure we were measuring outcome changes due to the uptake
in treatment rather than to any population differences. It was clear then that a given
patient should not be used as part of both the pre-IPTj and the post-IPTj cohorts, as
the patient’s age, comorbidities, and propensity to receive IPT would have progressed over
time. Less obviously, we should not randomly assign cohorts to each patient who had visits
during both periods, because the expected ages, comorbidities, and IPT propensities of those
randomly assigned to the pre- and post-IPTj cohorts, during the pre- and post-IPTj periods,
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respectively, would differ. Removing patients from analysis who were present during both
time periods would also induce population differences, both because the only new patients
left in the pre period must have stopped visiting before the post period for unknown reasons,
and because no patients who were advanced in their treatment would exist in the post period.
The option chosen to avoid these sources of bias was to limit the population of study to
new patients. By comparing new patients before and after IPT was available, the method
would specifically identify the effect of IPT on new patients to whom it was given. In other
words, the identified ATT refers only to those treated patients we define to be new. The
mechanism for patient selection was to study only those patients whose first visit, at time
Ti, was during either the pre- or post-IPTj periods; and also to define two additional time
periods, TD and TY , within which to detect treatment and outcome, respectively, following
their Ti. To be included, patients also needed to have at least one visit after Ti + TY (to
ensure their presence to receive IPT and experience ATBD until that time), and the entire
detection period needed to exist within the same pre-IPTj or post-IPTj period as Ti (to
ensure they could be assigned to only one cohort). Thus, our cohorts were effectively those
new patients whose treatment or outcome would likely be seen by us within a certain time
frame, regardless of what happened to them after that time frame. Each data point consisted
of a single patient and whether they received IPT and experienced ATBD within TD and
TY , respectively.
Once we established which visit patterns qualified a patient for inclusion, we defined what
number and timing of patients at a given facility would help produce reliable estimates of
the causal effect of IPT at that facility. In order to feel confident about the accuracy of the
pre- and post-IPTj outcome rates, we required that there be 100 patients in each cohort. As
the formula for the causal effect involves dividing by the proportion treated in the post-IPTj
period, this proportion needed to be large enough to ensure the stability of the estimate.
Therefore, to trust the estimate, we excluded any facilities with less than a 10% treatment
rate. Effectively, then, we required that at least 10 patients were treated in the post-IPTj
period.
After identifying these cohorts, we moved on to establish the five data points needed
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for SCQE. In the pre-IPTj period, we calculated the rate of ATBD both the treated and
untreated patients. Suggestions for δ, representing the unobservable expected change in
ATBD rates from the pre- to post-IPTj cohorts in lieu of any treatment, came both from
expert suggestions and from data. Such data included the observed change in ATBD rates in
facilities not using IPT over a similar time period; the ATBD rate change over the pre-IPTj
period in facilities that go on to use IPT; and, if we thought it reasonable to assume IPT
was applied uniformly over time at the implementing facilities (for instance, that no gradual
IPT use increase occurred), the ATBD rate change over the post-IPTj period.
It is important to remember that none of the data analysis to discover or verify δ is
part of, or required by, the method. Given that δ is innately unknowable and unverifiable,
attempts to estimate it empirically run the risk of generating overconfidence, rather than
the healthy skepticism that should accompany estimates from realistic experts in the field
of application. In fact, this type of analysis brought about application-specific challenges of
arguably greater difficulty than the method itself. We include a detailed explanation of this
process both because it highlights the care needed to claim that the pre- and post-treatment
populations are identical, and because it stimulated helpful developments in, and extensions
to, the method.
2.2 Dataset-Specific Challenges
One particular challenge in analysis was that no national identification number existed in
the Tanzanian healthcare system. There was no way to connect the records of individuals
visiting more than one facility, as each facility used a different identifier. As a result, some
patients who looked new in the data may have previously received treatment somewhere else,
while some genuinely new patients may have had subsequent visits at other facilities during
which they received IPT or a experienced ATBD. These issues, however, could only affect
our results if they had disparate probabilities of occurring during the pre- and post-IPTj
periods, and we do not believe this to be the case.
Another challenge was a lack of wholly reliable documentation of the outcome, and, to a
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lesser degree, the treatment. The two pieces of relevant data available to us for each patient
visit were a field for active TB screening results and another for both IPT and active TB
treatment status. The screening field included not just what method was used for active TB
screening, but also that screening’s result. If multiple screenings were performed during the
same visit, the caregiver had to choose a single result to report. The treatment field was
used to report the start, continuation, or cessation of both IPT and TB treatment (Isoniazid
use on active TB). Dr. Maokola advised us that due to the highly overloaded nature of the
screening variable, it might in fact be less reliable than TB treatment status in establishing
ATBD. As a result, we decided to use the start of anti-TB treatment to define the date of
ATBD, which is our outcome. Given that clinicians used this single treatment status field
for both TB and IPT, we imagine that the rate of coding entry error may be higher than
expected in a uni-purpose field. We intend to investigate this possibility in the future, but
settled with this field as the best option available at the time of this preliminary analysis.
Another complication in the analysis was that no list of facility IPT start dates existed.
Given that the definition of the pre- and post-IPTj cohorts, and thus the effect estimate, is
dependent on the date the facility begun using IPT, it was critical that we be able to impute
IPTj with confidence. In observing the pattern of individual patients being treated with IPT,
it became clear we could not assume that the first such instance in a given facility must be
the IPTj; many facilities had a small number of patient visits with supposed IPT treatment
starts months or years before a massive spike in treatment starts that clearly suggested the
facility-wide start to IPT use, IPTj. It is possible these early outliers were coding errors, or
perhaps genuine treatment starts from visiting clinicians who had received training on IPT.
Regardless of the cause, it became necessary to systematically establish IPTj from the time
series of IPT starts with these outliers in mind. In order to do this, we picked a certain
low percentile of patient IPT starts ordered by date. We declared that percentile’s date
the IPTj, and ignored all IPT starts before that point. Through manual review, we found
that the 2nd percentile tracked best with each facility’s large initial spike in IPT starts. A
sensitivity analysis showed that the causal effect estimates were robust to other choices of
percentile; comparison of the ATTs from SCQE when using the 1st or 5th percentiles showed
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no major differences. It must be acknowledged that, by using this 2nd percentile proxy, there
is a risk of attenuation bias. If any of the ignored IPT starts before that date were genuine,
some effect of the treatment could be improperly experienced in the pre period. If any of
the included IPT starts after that date were just coding errors, the treatment effect would
be watered down. Both of these problems would lead to an understatement of the ATT.
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CHAPTER 3
δ Selection and a Methodological Adjustment
3.1 Informing a Choice of δ
A critical stage in analysis was the process of choosing δ, the change in ATBD rates we would
expect had there been no IPT treatment uptake. Given that this value is an unobservable
counterfactual, eliciting a guess from someone with significant domain knowledge and ex-
perience was a priority. After sharing descriptive statistics with Dr. Maokola about the
pre-IPTj ATBD rates for those facilities that qualified for inclusion, he suggested that, due
to increasing clinician focus on and testing for active TB, we might have expected a small
yearly increase in diagnoses in lieu of IPT use. He suggested perhaps a 0.5-1.0% annual
increase, though he was not confident about the coverage of that range across all facilities,
and encouraged empirical inquiry about δ. Given that this prior was relatively weak, and
acknowledging the widely ranging ATBD rates across facilities, we agreed that we should
investigate in depth whether the data itself supported this range or called it into question.
Attempts to use empirical data for this purpose should always be accompanied by an ac-
knowledgement that any estimation of δ is in reality an estimation of the best guess at δ,
as no data provides the unknowable counterfactuals needed to identify it. We proceed with
our “estimation” while keeping this in mind to avoid overconfidence in any results.
As suggested earlier, these informative data were threefold: trends in ATBD rates in non-
implementing facilities, as well as trends in the pre- and post-IPTj periods of implementing
facilities. We thought it reasonable to expect changes in IPT usage over the post-IPTj
periods, and thus did not use this third source to inform our estimation of δ.
Observed pre-IPTj ATBD rate changes could be used in two ways. First, they could
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generate distinct δ estimates, δj, for each facility that qualified for effect estimation. And
second, if we were willing to assume that there exists some system-wide δ, rather than
independent changes in ATBD rates for each facility, we could combine this data across
facilities to estimate such a δ. Observed ATBD rate changes in non-implementing facilities
are of no use in estimating the facility-specific δj’s, but are certainly helpful in estimating
the system-wide δ if we assume one exists.
Our confidence in facility-specific δj’s would rely on the quantity and time period length of
pre-IPTj data. We expected the combination of data available for system-wide δ estimation
due to the added assumption would result in smaller standard errors. Indeed, during initial
attempts to calculate these two types of δ, the standard errors on the facility-specific version
had unworkably large standard errors, even in the largest facilities. While the range of
estimates included Dr. Maokola’s weak prior, these standard errors precluded our ability to
accept or reject it as reasonable.
As a result of this data-driven limitation, we decided to opt for estimation of a system-
wide δ. We intend to run experiments in the future on simulated data in which such a
system-wide δ does or does not exist, in order to identify the consequences of the assumption
being violated.
3.2 Managing Impossible Results
During the first attempts to calculate δ, we faced a major issue: estimates often resulted in
predictions that did not fall within the realm of possibility. For example, say we arrived at
a δ of -0.5% per year (that is, each year brought a decrease of a half percentage point in the
ATBD rate), and observed a facility with IPTj=1/1/2015 and an outcome rate change from
around 2% in 2012 to 1% in 2014. SCQE would then seem to be claiming the counterfactual
Y0 by 2017 was around -0.5%. Given that the outcome is a rate of disease development,
negative values do not make sense, which suggests that the estimate of δ was likely incorrect.
Even when using facility-specific δj’s, this was often an issue. Intuitively, when given the
trend explained above, we would expect that ATBD rate decrease to slow down significantly,
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perhaps guessing at a rate of 0.5% in 2017 in lieu of IPT implementation. And yet, had the
ATBD rate started at 10% in 2012 and shown the same -0.5% per year change through 2014,
we would have no reason to expect the same kind of leveling-off. The difference is that it
becomes harder to decrease the ATBD rate the closer we get to the 0% bound.
One way to avoid impossible results would be to ask Dr. Maokola for estimates of
E[Y (0)|T = 1] for each qualifying facility, rather than asking for a facility-wide estimate
of δ as we did. Alternatively, we can search for a methodological change that avoids these
impossible results and is generalizable to cases with too many facilities to generate estimates
by hand. A clear way of modeling this kind of decay toward 0 is by using an exponential
rather than a linear model, allowing for faster outcome rate decreases the farther we are from
the bound, and preventing extrapolation beyond it. We believe too that this pattern helps
lend credence to our assumption that a system-wide δ exists. Of course, the exponential
model loses its real-world interpretation if the outcome rate increases over time, but the
data available to us suggested a system-wide ATBD decay, so we continued analysis with
this shift in methodology. A similar, though subtler, instance of impossible results is an area
of current study for SCQE, and is discussed later.
3.3 Choosing δ
In implementing this change, we regressed the binary outcome on the first visit date for all
pre-IPTj and non-implementing patients using a binomial regression with a log link, and
included intercept terms for each facility. By exponentiating the estimated coefficient for
date, we obtained the daily ATBD risk ratio, 0.99980 (95% CI [0.99971, 0.99990]). We can
use this daily decay rate to calculate the expected facility-specific pre-to-post decay over the
length of time between the average pre-IPTj and average post-IPTj visits. For example,
over the course of one year we would expect a decay of 6.9% (95% CI [3.6%, 10.1%]). Given
each facility’s pre-IPTj outcome rate, this decay maps to a raw ATBD decrease that can be
plugged into the SCQE formula for the ATT.
There seems to be a difference between the original δ suggestion given by Dr. Maokola
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and the δ obtained using this process, though we make no claims about it being a significant
one. Given that Dr. Maokola clearly suggested that he did not have a strong prior about δ,
and encouraged a data-driven approach, we decided to continue with the analysis using the
latter. A multitude of factors beyond the system-wide increasing focus on TB testing had an
effect on long-term ATBD rates, and, though we make no claims about why the data shows
that rate decaying over time, we feel confident trusting that such decay occurred. Critically,
in order for the true δ to significantly differ from the δ suggested by the data, there had to
have been some other change occurring at implementing facilities that drove the observed
change in outcome rates. We do not have any evidence to suggest such a change existed, and
thus feel confident about the estimated δ, aside from the standard skepticism accompanying
the knowledge that unidentified confounders are always, inconveniently, unidentified.
Since the central assumption upon which this method’s inference relies is the value of
δ, the difference between the expert- and data-based estimates serves as a helpful reminder
that the inference is only as reliable as the assumptions underlying it. For cases in which
granular data that can empirically suggest a δ is not available, and for which there is not a
strong, domain-knowledge-based prior on the value of δ, estimates from SCQE should not
be trusted.
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CHAPTER 4
Results
For our calculation of the SCQE, we set both TD and TY to one year. These choices imply
that any IPT given in the one year after a patient’s first visit characterizes them as a
treated patient, and any ATBD reported in the same period gives them an outcome value
of 1. Making TY much longer would lead to a shrinking number of patients who qualify
for inclusion; making TD much shorter would exclude new patients who only received IPT
after some months but still felt its effects; and making TY shorter than TD would not have
a sensible interpretation. However, we plan to experiment with some other values of these
time periods as a robustness check.
The data available to us spanned visits by 336,226 patients across 318 HIV treatment
facilities from January 1, 2012 through September 30, 2017 (Table 4.1, column 1). For
a majority of these patients the first visit we observe in the data was in fact their first
treatment visit, though other patients had been seeking treatment for as many as 13 years
prior to 2012. After applying the requirements detailed above for inclusion in this SCQE,
we were left with 21 qualifying facilities and 26,715 qualifying patients (Table 4.1, columns
2-4). These facilities had imputed IPTj’s ranging from May 27, 2014 to January 4, 2016,
and the times between their pre- and post-IPTj visits, used to scale the ATBD risk ratio,
averaged 1032 days.
Combining the facility-specific pre- to post-IPTj times with the system-wide ATBD decay
rate point estimate produces the counterfactual ATBD decay for a facility’s whole population,
presented in Figure 4.1a. Facilities are arranged by number of patients, facility 1 being the
most visited. The start of each arrow is the observed pre-IPTj rate, while the end of each
arrow is the counterfactually untreated post-IPTj ATBD rate, E[Y (0)|T = 1]. That rate is
16
Table 4.1: Demographic information, separated by cohort.
Information drawn from each patient’s first occurrence in the dataset. All patients are included in column
1, and the subset of qualifying new patients (as defined in section II) are separated by time period and
treatment status in columns 2 through 4. The WHO clinical stage classifies patients from 1
(asymptomatic) to 4 (AIDS) [10].
Qualifying Patients
All patients in data Pre-period
Post-period
Treated
Post-period
Untreated
Number of Patients 336,226 151,165 2,801 8749
Number of Facilities 318 21
Patients per facility, me-
dian (mean ± sd)
331 (1057 ± 2143) 662 (772 ± 326) 90 (133 ± 105) 283 (417 ± 371)
Male, % 31.2% 29.3% 28.0% 32.8%
Age, median (mean ± sd) 35 (34.9 ± 12.7) 34 (34.3 ± 12.1) 36 (36.0 ± 10.6) 35 (34.5 ± 12.8)
WHO clinical stage, me-
dian (mean ± sd)
2 (2.26 ± 0.99) 2 (2.27 ± 0.99) 2 (2.24 ± 0.91) 3 (2.28 ± 0.94)
Days since first HIV clinic
visit, median (mean ± sd)
0 (440 ± 737) 0 (0 ± 0)
not observed, but is the result of scaling the ATBD risk ratio to each facility’s average pre-
to-post-IPTj time periods. In Figure 4.1b, we layer in the portion of that rate we do observe,
E[Y (0)|T = 1, D = 0], as squares. We also plot the observed ATBD rate for the treated,
E[Y (1)|T = 1, D = 1], as solid circles. Finally, we use the LIE to calculate the counterfactual
non-treatment ATBD rate for those who were treated, E[Y (0)|T = 1, D = 1], and plot them
as hollow circles in Figure 4.2. The differences between these observed (solid circles) and
counterfactual (hollow circles) outcome rates form the SCQE’s ATT point estimates. All of
the counterfactuals plotted in Figures 4.1 and 4.2 are the point estimates produced using
the central 0.99980 daily decay rate from the binomial regression, rather than confidence
intervals. The presence of counterfactuals in the negative area of Figure 4.2 are concerning
and will be addressed in Chapter 6.
A continuing area of research on SCQE are its standard errors. Because we have patient-
level data in this application, we were able to utilize this method’s similarity to an instru-
mental variables approach and the established variance formulas that come with it[11]. As
17
Figure 4.1: Counterfactual ATBD rate change
Changing ATBD rates at qualifying facilities, ordered from most to least populous. (a) Counterfactual
ATBD shift under non-treatment over time. The pre period rate is observed while the post period is not,
as some post period patients were in fact treated. (b) Layering on the observed ATBD rates in the post
period by treatment status given.
(a)
(b)
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Figure 4.2: Counterfactual ATBD rate change
Layering on the counterfactual non-treatment ATBD for those patients who did receive treatment, as
imputed by SCQE. Negative rates are discussed in Chapter 6. The difference between these unobserved
non-treatment rates and the corresponding observed treated rates form the ATT point estimates.
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Figure 4.3: SCQE ATT Estimates
ATT estimates for each facility, calculated by subtracting the treated patients’ counterfactual
non-treatment ATBD rate from their observed ATBD rate under treatment. The thick lines represent the
range of likely point estimates produced by plugging in the calculated 95% CI of δ values. The whiskers
represent the 95% CI produced by the IV standard errors, appended to the highest and lowest likely point
estimates.
IV does not allow for a δ, we adjusted the data itself in a way that tricked the formula into
accounting for it. The IV variance includes an acknowledgment of sampling error across the
data, as well as variability in the treatment rate. It does not, however, take into account
the variability of δ itself. As a stopgap before independently developing an all-encompassing
variance formula, we simply have the IV formula generate a 95% CI on each end of the 95%
confidence interval on δ that was generated by the binomial regression. This allows us to
plot the ATT for each facility in Figure 4.3, in which our point estimates take the form of
ranges, with an attached confidence interval.
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CHAPTER 5
Preliminary Application Conclusions and Threats to
Validity
Because this is the first time SCQE has been applied to real-world data, we find it critical to
define a correct interpretation of the causal effect estimates. We claim that these preliminary
results do not show much evidence that the Tanzanian IPT implementation program sys-
tematically lowered ATBD rates in the new patients who were given it. However, this should
not be interpreted as suggesting that IPT is not effective at preventing ATBD. Instead, it
suggests that the patients who were assigned IPT may not have been those at highest risk of
ATBD in the first place. This conclusion differs wildly from the one we might have reached
by naively comparing the low ATBD rates in the treated population to the higher rates
in the untreated population. That conclusion would likely have been far more optimistic,
perhaps claiming that the low ATBD rates among the treated patients were caused by their
treatment, and pointing out that the untreated patients had much higher rates. These mis-
interpretations demonstrate the critical need for counterfactual thinking and methodologies
that use it.
SCQE does not diagnose what characteristics put patients at risk for TB. It reveals how
those who are given treatment vary from those who are not on their non-treatment potential
outcomes, a useful hint into understanding these populations. This tool can accompany any
other differences between the groups in offering suggestions about why caregivers decided to
give IPT to specific patients; why those given IPT may have been less likely to experience
ATBD; or which patients should be given extra attention in attempts to select those who
may benefit most from treatment.
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Several decisions made during the analysis process may present threats to the validity of
these preliminary results. We intend to address each potential threat during our continuing
work on this application and on SCQE in general, and to detail both the concerns and our
proposed solutions here.
It is possible that these preliminary results apply only to this specific subset of treated
patients (new patients with at least one visit after TY ) and that there was a significant
reduction of ATBD in other treated subpopulations given IPT, though we cannot think of
any reason to suspect this distinction. Even if such a difference existed, it may not alter long-
term policy-focused responses if the effect of IPT on new patients is of particular interest.
Indeed, the longer an IPT program exists, the higher the proportion of treated patients we
might expect to be new, as fewer long-term patients remain untreated. In this way, the
methodologically-driven decision to analyze only new patients may not be as much of a
limitation as it seemed, especially given SCQE’s focus on effectiveness rather than efficacy.
The imputation of IPTj’s carries with it uncertainty, even though sensitivity analysis
showed the results to be robust to different choices of IPTj. We hope that fieldwork and
review of records may help to verify these dates in order to remove this uncertainty and
possible attenuation bias. Furthermore, using the length of time between the average pre-
IPTj and average post-IPTj visits to scale the expected outcome decay over that time is a
biased method, because the outcome rate is not linear. We plan to engage with methods
that avoid this bias.
As mentioned earlier, we intend to rerun this analysis with different values of TD and
TY . We will also be running simulations to measure the response of the method to whether
or not a system-wide δ truly exists. And finally, we plan to investigate the differences in
patient characteristics between those who are and are not given IPT, in the hope that this
may help to explain why some were given IPT and whether that could relate to their ATBD
risk, and also to determine which populations to target in future IPT administration.
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CHAPTER 6
Future Work
6.1 Methodological Development
A feature of this treatment that strengthens the validity of our inference is that caregivers,
rather than patients, made the treatment decisions. Though SCQE allows for self-selection
into treatment, we may worry in such cases that those who actively choose not to use a treat-
ment might change their general treatment decisions in some way due to that choice. These
choices could in turn affect their outcome in some way other than through this treatment.
However, those not assigned IPT were presumably unaware that such treatment existed and
was being given to other patients. Another benefit of this treatment in particular is that we
believe no resources were diverted from untreated patients in order to carry out treatment.
For treatments that use up scarce resources, such as limited clinician time or medication
supply, it is usually a concern that treatment could affect the untreated population through
a residual loss in resources. In this case, however, IPT use did not to our knowledge expend
any limited resource. Both of these potential concerns are closely related to common topics
in IV, where they would constitute violations of the exclusion restriction. We think it is
important to actively check for such violations within the new framework.
As mentioned earlier, a central area of further study for this method, and particularly
within this application, involves the management of results that are not rationally possible.
Though our switch from linear to exponential outcome changes avoided the imputation of
negative E[Y (0)|T = 1] values, there are instances of particular subsets of those post-IPTj
cohorts that have negative imputed outcome rates. For example, if our estimate of δ suggests
that E[Y (0)|T = 1] = 1% for a facility in which 20% of such post-period patients are treated,
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and we observe a sample indicating E[Y (0)|T = 0, D = 1] = 2%, the LIE suggests it must be
the case that E[Y (0)|T = 1, D = 1] = −3%. In this case δ alone did not lead us to impute a
negative outcome rate, but when combined with the outcome rate among untreated patients,
it resulted in the problem within the treated subset. We see 13 examples of this happening
in Figure 4.1c, represented by hollow circles to the left of 0. This is clearly a significant
problem, as the subset’s imputed value constitutes one half of the difference we claim to be
the ATT. And while earlier we were able to shift our δ generation process to both avoid
impossible values and track with real-life processes, we have not yet discovered a sensible
way to avoid this issue in all cases.
It is important to remember here that the LIE doesn’t lie: if a negative value is imputed,
it must be the case that the treatment or outcome rates were noisy or the δ was incorrect.
We would expect that noise could generate a small number of the impossible E[Y (0)|T =
1, D = 1] imputed values, which would not signal a broader issue with δ. Thus, we must
ask both whether results we are faced with could be attributed to noise, and, whatever we
conclude, what to do with them. When we have a variety of estimates, as in this application
involving several facilities, deciding whether these cases are acceptable outliers is somewhat
easier than cases involving a single treatment use, as we can observe the rate at which this
occurs. Even with multiple uses though, it is much harder to claim that a barely impossible
value is noise-driven than that a significantly impossible value is not noise-driven.
Three subtypes of this problem perhaps deserve different responses: a positive estimate
with a confidence interval that includes negative values, a negative estimate with a confidence
interval that includes positive values, and a statistically significant negative estimate. The
first situation is one that has plagued statisticians but does not present a pressing threat
to CE estimate validity. The second and third, different due only to the classical reliance
on a particular significance level, require us to decide whether to learn from or change our
estimates. Should we adjust the estimate to be 0 and move forward? Should we claim an
inability to produce effect estimates in that application? Should we learn from this value,
adjusting δ until the problem no longer occurs? A critical consideration is that, around a
bound, such adjustment and learning will probably occur in only one direction; i.e. it will be
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clear whether our imputed values are too low, but rarely, if ever, whether they are too high.
This could easily bias results against causal attribution of major increases in the outcome
rate.
What is clear is that these values can easily result in nonsensical conclusions. For example,
in the above demonstration, it would be unreasonable to claim IPT made 4% of patients
develop active TB, given that only 1% of those who were treated actually experienced ATBD.
We believe that, though further research may adjust our level of confidence in our results
or may alter the point estimates to a degree, decisions about how to deal with this issue in
particular have the potential to drastically change the major conclusions presented in this
preliminary report.
6.2 Standard Error Development
We have begun the work of developing a variance formula for SCQE’s effect estimate that
does not require the patient-level data needed to generate IV standard errors. In this early
stage, we make two major assumptions to simplify the derivation. First, we assume ho-
moskedastic errors, that Var
(
Y (D |T,D′)
)
= σ2 ∀ D,T,D′. And second, we assume that
the proportion treated, pi, is fixed rather than a random variable.
With these two assumptions in mind, we imagine the theoretical equation representing
the true development of non-treatment outcomes over time,
E[Y (0)|T = 0] + δ = E[Y (1)|T = 1] (6.1)
where E[Y (0)|T = 0] and E[Y (0)|T = 1] are the theoretical non-treatment potential out-
comes in the pre and post periods, respectively, and δ is the theoretical difference between
them. Instead of observing E[Y (0)|T = 0], we observe a finite sample average we notate as
Y (0 |T = 0), and we call their difference η0, such that
E[Y (0)|T = 0] + η0 = Y (0 |T = 0) (6.2)
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Similarly, for the post period, we can write that
E[Y (0)|T = 1] + η1 = Y (0 |T = 1) (6.3)
Note that
Var(η0) = Var
(
E[Y (0)|T = 0] + η0
)
(6.4)
= Var
(
Y (0 |T = 0)
)
(6.5)
=
σ2
NT=0
(6.6)
and that
Var(η1) = Var
(
E[Y (0)|T = 1] + η1
)
(6.7)
= Var
(
Y (0 |T = 1)
)
(6.8)
=
σ2
NT=1
(6.9)
where NT=0 and NT=1 are the number of pre and post patients, respectively.
Combining equations 6.1, 6.2, and 6.3,
Y (0 |T = 0)− η0 + δ = Y (0 |T = 1)− η1 (6.10)
Y (0 |T = 0) + [δ + η1 − η0] = Y (0 |T = 1) (6.11)
in which we can view δ˜ := δ + η1 − η0 as a kind of “sample delta.”
Now we can mimic equation 1.3 to create a sample version of the SCQE’s ATT:
ATT = Y (1 |T = 1, D = 1)−
(
Y (0 |T = 0)− Y (0 |T = 1, D = 0)(1− pi) + δ˜
pi
)
(6.12)
= Y (1 |T = 1, D = 1)− pi−1
(
Y (0 |T = 0)− Y (0 |T = 1, D = 0)(1− pi) + δ + η1 − η0
)
(6.13)
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If we now take the variance of the ATT , we can utilize the independence of the sample
averages involved to simplify.
Var
(
ATT
)
= Var
(
Y (1 |T = 1, D = 1))+ pi−2Var(Y (0 |T = 0)−
Y (0 |T = 1, D = 0)(1− pi) + δ + η1 − η0
)
(6.14)
= Var
(
Y (1 |T = 1, D = 1))+ pi−2(Var(Y (0 |T = 0))+
(1− pi)2Var(Y (0 |T = 1, D = 0))+ Var(η1)+ Var(η0) ) (6.15)
=
σ2
NT=1,D=1
+ pi−2
( σ2
NT=0
+ (1− pi)2 σ
2
NT=1,D=0
+
σ2
NT=1
+
σ2
NT=0
)
(6.16)
=
σ2
NT=1,D=1
+ pi−2
( 2σ2
NT=0
+ (1− pi)2 σ
2
NT=1,D=0
+
σ2
NT=1
)
(6.17)
This is an overly simplified formula due in large part to the assumptions of homoskedastic
errors and a fixed pi, but it demonstrates the work already underway to develop a robust
measure of this SCQE’s variance.
Work on this application has added some best practices and extensions to Hazlett’s
original method. We explored a new way to adjust for non-linear trends in outcome and to
incorporate those results into the original formula for the ATT. This adjustment also avoided
the most flagrant generation of impossible results. Work on subtler cases is underway. We
suggested that the SCQE’s estimates might be more accurate when the treatment selection
method is blind to those who are not treated and when treatment does not change the
experiences of those that are not treated. We also presented our early attempts to derive
the variance of the ATT. We hope that the details presented here encourage caution by
those excited to use this powerful and helpful tool, especially in trusting estimates of δ and
assuming the similarity of pre- and post-period cohorts.
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